No abstract available.
Diagnosis* ; Echocardiography*

No abstract available.
Bacteria* ; Ulsan*

No abstract available.
Enzyme-Linked Immunosorbent Assay*

No abstract available.
Enzyme-Linked Immunosorbent Assay*

No abstract available.
Enzyme-Linked Immunosorbent Assay*

No abstract available.
Head* ; Neck*

Purpose: To retrospectively evaluate the chest computed tomography (CT) findings of coronavirus disease 2019 (COVID-19) in patients with mild clinical symptoms at a single hospital in South Korea. Materials and Methods: CT scans of 87 COVID-19 patients [43 men and 44 women; median age:41 years (interquartile range: 26.1–51.0 years)] with mild clinical symptoms (fever < 38℃ and no dyspnea) were evaluated. Results: CT findings were normal in 39 (44.8%) and abnormal in 48 (55.2%) patients. Among the 48 patients with lung opacities, 17 (35.4%) had unilateral disease and 31 (64.6%) had bilateral disease. One (2.1%) patient showed subpleural distribution, 9 (18.8%) showed peribronchovascular distribution, and 38 (79.2%) showed subpleural and peribronchovascular distributions.Twenty-two (45.8%) patients had pure ground-glass opacities (GGOs) with no consolidation, 17 (35.4%) had mixed opacities dominated by GGOs, and 9 (18.8%) had mixed opacities dominated by consolidation. No patients demonstrated consolidation without GGOs. Conclusion The most common CT finding of COVID-19 in patients with mild clinical symptoms was bilateral multiple GGO-dominant lesions with subpleural and peribronchovascular distribution and lower lung predilection. The initial chest CT of almost half of COVID-19 patients with mild clinical symptoms showed no lung parenchymal lesions. Compared to relatively severe cases, mild cases were more likely to manifest as unilateral disease with pure GGOs or GGOdominant mixed opacities and less likely to show air bronchogram.

No abstract available.
Glycopeptides*

BACKGROUND: The currently available ldegrees Cal anesthetics have limitations in action duration. The duration ranges from 3 to 8 hours. Long acting anesthetic agents are particularly desirable to manage postoperative pain, relieve severe pain assdegrees Ciated with terminal cancer, and for nerve bldegrees Cks carried out in pain clinics. In this paper mixture of ldegrees Cal anesthetics was formulated into cylindrical pellet using biodegradable polymer and its efficacy and safety was evaluated. METHODS: Pellets were prepared by modified melting prdegrees Cess with biodegradable polyester 30 wt%, bupivacaine 35 wt%, liddegrees Caine 35 wt% and dexamethasone 0.05 wt% of polymer and drug. In vitro release kinetics of ldegrees Cal anesthetics from pellet were determined in PBS at pH 7.4, 37degrees C, and the released ldegrees Cal anesthetics were analyzed by HPLC. Nine male Sprague Dawley weighing 300~350 gm were implanted with pellets along the sciatic nerve and the sensory bldegrees Ckade was assessed by an analgesiometer. The duration data were analyzed by paired t-test using SAS 6.11. RESULTS: Ldegrees Cal anesthetics were released in a controlled manner in vitro. In general, 40~50% of the drug released for the first day, and thereafter approximately 5% released daily. Sensory bldegrees Ckade lasted to beyond 2 days at the dose of 7 mg/100 g bupivacaine and liddegrees Caine respectively. All of the animals exhibited no systemic toxicity and complete recovery. CONCLUSIONS: The results indicated that the mixture pellet demonstrated efficient and safe in prolongation of sensory bldegrees Ckade for significant period of time. The mechanisms underlying the mixture effect are under investigation.
Anesthetics* ; Animals ; Bupivacaine ; Chromatography, High Pressure Liquid ; Dexamethasone ; Freezing ; Humans ; Hydrogen-Ion Concentration ; Kinetics ; Male ; Pain Clinics ; Pain, Postoperative ; Polyesters ; Polymers* ; Sciatic Nerve

BACKGROUND: Despite of numerous researches on the mechanisms and new therapeutic methods of chronic pain, patients are still suffering even with the help of opioids. In recent years, however, with the development of molecular-biology cell transplantation gives us a new chance for treating intractable chronic pain. The major purpose of the present study was to determine if the chromaffin cells have robust analgesic effects in the spinal atlanto-occipital subarachnoid space even without nicotine stimulation. METHODS: In order to determine whether cultured bovine adrenal medullary chromaffin cells transplanted in the spinal cord can produce analgesic effects, we purified adrenal medullary chromaffin cells and implanted them into the subarachnoid space of rats' (n = 10) spinal cord without immunosuppression, and investigated the hot sensitivity of rats' hind-paw by a light-beam test. RESULTS: It was found that compared with the control group, hot response latency of the group which received adrenal medullary chromaffin cells had increased at 14 days and the analgesic efficacy was maintained for at least 3 months. CONCLUSIONS: Adrenal medullary chromaffin cells transplanted in the rats' spinal cord may provide a permanent and locally available source of neuropeptides for the relief of intractable pain. Furthermore, these kinds of analgesic effect even produced without any stimulation such as nicotine.
Analgesics, Opioid ; Animals ; Cell Transplantation ; Chromaffin Cells* ; Chronic Pain ; Humans ; Immunosuppression ; Neuropeptides ; Nicotine ; Pain, Intractable ; Rats* ; Reaction Time ; Spinal Cord* ; Subarachnoid Space ; Transplants